Medtronic updates Abre venous stent instructions with manual deployment option for partial placement
Medtronic has revised the Abre self-expanding venous stent IFU to add an approved manual deployment alternative, aimed at limiting harm if a stent is only partially deployed.
Medtronic has told users of its Abre self-expanding venous stent system that the product's instructions for use have been updated. The notice was published by the Dutch health inspectorate, IGJ, and carries a notice date of 16 October 2026; the IGJ page is dated 21 October, while the downloadable document is labelled 22 October 2026.
According to the notice, the update provides an approved alternative solution involving manual deployment. Its stated purpose is to limit the potential harmful consequences in the rare event of partial stent placement.
The communication is a manufacturer's Field Safety Notice. Medtronic, Inc. is listed as the manufacturer and Medtronic B.V. as its authorised representative. The notice is available as a six-page PDF.
The text provided does not state how many devices or incidents are involved, whether any patient harm has been reported, or what root cause lies behind the partial-deployment scenario. It also does not say whether any devices must be returned or quarantined.
As general context, manufacturers must monitor their devices after they reach the market and take action where users are at risk. They inform users and the competent authority through field safety notices.
What it means for your team
- Clinical and procurement teams using Abre should obtain and review the revised IFU and the full six-page notice from the IGJ page.
- Quality and vigilance teams should check that the updated IFU is distributed and that staff training records reflect the new manual deployment method.
- Teams should confirm any additional actions or reporting requirements directly with Medtronic B.V., as the available text gives no detail on incident numbers or root cause.
Article written by VigiEye from the official source (IGJ). AI-assisted; check the source before acting.
Market accessCompany releaseMedicare begins paying for Lucid's EsoGuard as PAVmed's Veris nears FDA 510(k) filing
Market accessOfficialDenmark updates Voltabak eye drop supply notice, with shortage expected to run to mid-May 2027
Market accessOfficialMethergin 0.2 mg/ml injection withdrawn from Danish market, DKMA reports
Market accessOfficialDenmark updates import window for estradiol 25 microgram patches in supply failure
Market accessOfficialDKMA updates Vivelle Dot 37.5 supply notice: shortage expected to last until end of December
Market accessOfficial